Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives $110.00 Consensus Target Price from Brokerages

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) have received a consensus rating of “Moderate Buy” from the eighteen research firms that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, thirteen have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $110.00.

GPCR has been the subject of several recent research reports. Leerink Partners reiterated an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. William Blair reissued an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Thursday, January 22nd. Citizens Jmp cut their target price on Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a research note on Friday, February 27th. Finally, HC Wainwright cut their target price on Structure Therapeutics from $114.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, March 16th.

Hedge Funds Weigh In On Structure Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Osaic Holdings Inc. raised its holdings in Structure Therapeutics by 101.9% in the 2nd quarter. Osaic Holdings Inc. now owns 63,362 shares of the company’s stock worth $1,314,000 after acquiring an additional 31,972 shares during the last quarter. Aberdeen Group plc raised its holdings in Structure Therapeutics by 46.1% in the 3rd quarter. Aberdeen Group plc now owns 586,869 shares of the company’s stock worth $16,432,000 after acquiring an additional 185,245 shares during the last quarter. Jefferies Financial Group Inc. purchased a new position in Structure Therapeutics in the 3rd quarter worth approximately $4,770,000. Birchview Capital LP purchased a new position in Structure Therapeutics in the 2nd quarter worth approximately $747,000. Finally, Private Capital Advisors Inc. purchased a new position in Structure Therapeutics in the 3rd quarter worth approximately $1,545,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Structure Therapeutics Stock Down 1.1%

Shares of GPCR stock opened at $54.51 on Friday. The business’s fifty day moving average is $61.18 and its 200 day moving average is $53.47. Structure Therapeutics has a twelve month low of $15.00 and a twelve month high of $94.90. The stock has a market cap of $3.86 billion, a price-to-earnings ratio of -69.00 and a beta of -1.17.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.14). Equities research analysts expect that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.